Stocktoria

Rani Therapeutics Holdings, Inc. RANI

Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2021-07-30

Rani Therapeutics Holdings, Inc. statistics & valuation

Market cap$100.3M
P / S61.4×
P / B2.4×
Net margin-1817.1%
Return on equity-71.5%
FCF margin-1151.4%
Net cash$18.6M
Enterprise value USD$81.7M
Earnings yield EBIT/EV-46.9%
Return on capital-83.4%

Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.

Profitability & efficiency

Net margin (%)
-306.60% -2920.00% -1817.10% 202020212022202320242025
Gross margin (%)
202020212022202320242025
Operating margin (%)
-3581.00% -1899.10% -5186.20% -2346.00% 202020212022202320242025
Return on equity (%)
-6.90% -41.30% -133.50% -859.40% -71.50% 202020212022202320242025
Shares outstanding
19534 23817 25505 28476 66138 202020212022202320242025
Net debt ($)
-$70.6M -$117.5M $3.0M $24.1M $21.2M -$18.6M 202020212022202320242025
Share buybacks ($)
202020212022202320242025
Return on assets (%)
-6.70% -28.30% -58.70% -81.90% -50.60% 202020212022202320242025
Free cash flow margin (%)
-3497.80% -1205.40% -3479.00% -1151.40% 202020212022202320242025
Debt / equity (×)
0.00× 0.41× 1.18× 7.16× 0.00× 202020212022202320242025
EPS ($)
-$0.43 -$1.28 -$1.33 -$1.05 -$0.45 202020212022202320242025

Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).

Key ratios (by fiscal year)

RatioFY2025FY2024FY2023FY2022FY2021FY2020
Operating margin-2346.0%-5186.2%——-1899.1%-3581.0%
Net margin-1817.1%-2920.0%——-306.6%—
FCF margin-1151.4%-3479.0%——-1205.4%-3497.8%
Return on assets-50.6%-81.9%-58.7%-28.3%-6.7%—
Return on equity-71.5%-859.4%-133.5%-41.3%-6.9%—
Debt / equity0.00×7.16×1.18×0.41×0.00×-0.02×
Current ratio4.211.506.3620.9645.3014.12

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.